We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Portable Device Finds Sepsis Infection Markers

By LabMedica International staff writers
Posted on 20 Jul 2017
A new portable device can quickly find markers of deadly, unpredictable sepsis infection from a single drop of blood, which is the first to provide rapid, point-of-care measurement of the immune system's response, without any need to process the blood.

Sepsis is routinely detected by monitoring patients' vital signs, such as blood pressure, oxygen levels, temperature and others. More...
If a patient shows signs of being septic, the doctors try to identify the source of the infection with blood cultures and other tests that can take days, time the patient may not have. The new device takes a different approach.

Scientists at the University of Illinois at Urbana-Champaign (Urbana, IL, USA) and their colleagues tested the device with blood samples from patients in the intensive care unit (ICU) and emergency room. When a physician suspected infection and ordered a blood test, a small drop of the blood drawn was given to the team, stripped of identifying information to preserve patient confidentiality. The team was able to monitor CD64 levels over time, correlating them with the patient's vital signs. They found that the results from the rapid test correlated well with the results from the traditional tests and with the patients' vital signs. The small, lab-on-a-chip device counts white blood cells in total as well as specific white blood cells called neutrophils, and measures a protein marker called CD64 on the surface of neutrophils. The levels of CD64 surge as the patient's immune response increases.

Rashid Bashir, PhD, a professor of bioengineering and lead investigator, said, “We are looking at the immune response, rather than focusing on identifying the source of the infection. One person's immune system might respond differently from somebody else's to the same infection. In some cases, the immune system will respond before the infection is detectable. This test can complement bacterial detection and identification. We think we need both approaches: detect the pathogen, but also monitor the immune response.”

The team is working to incorporate measurements for other inflammation markers into the rapid-testing device to give a more complete picture of the body's response, and to enable earlier detection. They also have a startup company, Prenosis Inc (Champaign, IL, USA) that is working to commercialize the device. The study was published on July 3, 2017, in the journal Nature Communications.

Related Links:
University of Illinois at Urbana-Champaign
Prenosis

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.